According to Kalorama, cancer pain is one of the most consistently experienced pain and a fast growing area for the industry because it had been previously untreated.
New York, NY (PRWEB) June 03, 2013
The world market for pain management drugs and devices reached $34.9 billion in 2012, growing at a rate of 2.9% from 2010 to 2012. The market is growing as a result of the aging population, but also increased awareness of pain and the need for treatment, among other factors. The finding was made in Kalorama Information’s report, “The World Market for Pain Management Drugs and Devices.”
Surgical pain, burn pain and musculoskeletal pain are among the top areas of pain treatment. But according to Kalorama, cancer pain is one of the most consistently experienced pain and a fast growing area for the industry because it had been previously untreated. Extensive studies have been done for the past two decades documenting that significant pain is experienced by large numbers of patients with metastatic cancer. These studies have forced a reevaluation of the association between disease stage and the onset of pain due to cancer. Prior to these studies, it was thought that cancer pain was limited to far-advanced disease and not earlier stages. The majority of patients, approximately 60% to 80%, with far-advanced cancer will need careful pain management due to significant pain.
Despite all the availability of pain management products, cancer pain is one of many areas of pain that is often poorly managed. A growing body of research is documenting the relative importance of multiple potential barriers to pain control, according to the report. Some of these barriers have been clearly identified, others have been suggested. However, more research is needed to fully understand the impact of pain management.
“Patients may be unwilling to inform health care professionals when they have pain, may attempt to minimize its severity, or may be frightened of taking potent analgesics to control their pain,” said Mary Ann Crandall, the report’s author.
According to Kalorama Information’s report, Between 30% and 75% of individuals with cancer experience moderate to severe pain depending on the stage of the disease, despite the fact that studies have shown cancer pain can be well managed in up to 90% of patients. Pain is most common in the patient with bone disease, but cancer-related conditions such as decubitus ulcers, cancer therapy, and pain related to the cancer itself also contribute significantly to the patient’s pain experience.
The narcotic pharmaceutical market is dominated by extended release formulations of generic mu-receptor agonists such as morphine, meperidine, fentanyl, and oxycodone. The leading products are Purdue’s Oxycontin (extended release oxycodone), with combined sales nearing 3 billion. Other products are Pfizer’s Lyrica and Celebrex; Eli Lilly’s Cymbalta; and Endo’s Lidoderm. Many products have lost patent protection and are open to generic competition, which has been gathering an increasing share of the market for pain management products. There are also devices used to treat pain, which are covered in the report.
Revenues earned by these brands, market share of competitors, products in development and markets by type of pain segment are all part of Kalorama Information’s report: “The World Market for Pain Management Drugs and Devices.” The report contains more information on the market size, forecast and can be purchased from Kalorama Information at: http://www.kaloramainformation.com/Pain-Management-Drugs-7579512/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.